Can hepatitis c treatment start safely in pregnancy? new study aims to find out
NCT ID NCT06367465
First seen Jan 05, 2026 · Last updated Jun 23, 2026 · Updated 16 times
Summary
This study looks at whether starting hepatitis C treatment during pregnancy is feasible and acceptable for women who have used drugs. Fifty pregnant adults with hepatitis C will take glecaprevir-pibrentasvir daily for 56 days. Researchers will track how well participants stick to the medication and how satisfied they are with the process, aiming to improve care for this vulnerable group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREGNANCY COMPLICATIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Barnes Jewish Hospital
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Washington Univeristy
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Glecaprevir-pibrentasvir (an oral hepatitis C medication)
What this could lead to
If successful, this could show that treating hepatitis C during pregnancy is practical and well-tolerated, potentially reducing mother-to-child transmission and improving long-term health for both.
What could go wrong
This is a small, early feasibility study with only 50 participants, so results may not apply to all pregnant women. Adherence may be challenging, and the study does not yet prove long-term safety or cure.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.